These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28697759)

  • 21. Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene.
    Lai CK; Moon Y; Kuchenbauer F; Starzcynowski DT; Argiropoulos B; Yung E; Beer P; Schwarzer A; Sharma A; Park G; Leung M; Lin G; Vollett S; Fung S; Eaves CJ; Karsan A; Weng AP; Humphries RK; Heuser M
    PLoS One; 2014; 9(11):e112671. PubMed ID: 25401736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation.
    Wang W; Zhang X; Li Y; Shen J; Li Y; Xing W; Bai J; Shi J; Zhou Y
    Stem Cell Rev Rep; 2024 Oct; 20(7):1889-1901. PubMed ID: 38884929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
    Fujino T
    Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
    Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
    Kunimoto H; Nakajima H
    Int J Hematol; 2017 Jul; 106(1):34-44. PubMed ID: 28555413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis.
    Hosen N; Shirakata T; Nishida S; Yanagihara M; Tsuboi A; Kawakami M; Oji Y; Oka Y; Okabe M; Tan B; Sugiyama H; Weissman IL
    Leukemia; 2007 Aug; 21(8):1783-91. PubMed ID: 17525726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.
    Zhang P; Xing C; Rhodes SD; He Y; Deng K; Li Z; He F; Zhu C; Nguyen L; Zhou Y; Chen S; Mohammad KS; Guise TA; Abdel-Wahab O; Xu M; Wang QF; Yang FC
    Stem Cell Reports; 2016 Jun; 6(6):914-925. PubMed ID: 27237378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance of the functional integrity of mouse hematopoiesis by EED and promotion of leukemogenesis by EED haploinsufficiency.
    Ikeda K; Ueda T; Yamasaki N; Nakata Y; Sera Y; Nagamachi A; Miyama T; Kobayashi H; Takubo K; Kanai A; Oda H; Wolff L; Honda Z; Ichinohe T; Matsubara A; Suda T; Inaba T; Honda H
    Sci Rep; 2016 Jul; 6():29454. PubMed ID: 27432459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDS-like experimental myelodysplasia: multilineage abnormal hematopoiesis in transgenic mice harboring the SV40 large T antigen under an immunoglobulin enhancer.
    Furuta Y; Aizawa S; Suda Y; Ikawa Y; Nishikawa S; Hayashi S; Hirabayashi Y; Inoue T
    Exp Hematol; 1993 Jun; 21(6):806-15. PubMed ID: 8500578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates.
    Zhang P; Chen Z; Li R; Guo Y; Shi H; Bai J; Yang H; Sheng M; Li Z; Li Z; Li J; Chen S; Yuan W; Cheng T; Xu M; Zhou Y; Yang FC
    Cell Discov; 2018; 4():4. PubMed ID: 29423272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
    Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
    Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells.
    Hilgendorf S; Folkerts H; Schuringa JJ; Vellenga E
    Exp Hematol; 2016 Dec; 44(12):1188-1196.e6. PubMed ID: 27616637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia.
    Heuser M; Park G; Moon Y; Berg T; Xiang P; Kuchenbauer F; Vollett S; Lai C; Humphries RK
    Exp Hematol; 2010 Mar; 38(3):174-9. PubMed ID: 20096329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
    An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
    Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of a xenograft model of human myelodysplastic syndromes.
    Muguruma Y; Matsushita H; Yahata T; Yumino S; Tanaka Y; Miyachi H; Ogawa Y; Kawada H; Ito M; Ando K
    Haematologica; 2011 Apr; 96(4):543-51. PubMed ID: 21193418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of the tumor suppressor BAP1 causes myeloid transformation.
    Dey A; Seshasayee D; Noubade R; French DM; Liu J; Chaurushiya MS; Kirkpatrick DS; Pham VC; Lill JR; Bakalarski CE; Wu J; Phu L; Katavolos P; LaFave LM; Abdel-Wahab O; Modrusan Z; Seshagiri S; Dong K; Lin Z; Balazs M; Suriben R; Newton K; Hymowitz S; Garcia-Manero G; Martin F; Levine RL; Dixit VM
    Science; 2012 Sep; 337(6101):1541-6. PubMed ID: 22878500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
    Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
    J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.